Matt Timmins

Haematology SpR/ACF, previous CRUK CRTF. Lymphoma and the tumour microenvironment

[Kate Cwynarski @CwynKate]

A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial

https://t.co/ttbcWkeaJf

[Joanna Krupka @AshaKrupka]

🎄NEW PAPER ALERT! 🎄First findings from our prospective DIRECT study were just published online @JCO_ASCO. We developed an open-source analytical pipeline (AULE) to track hundreds of phased variants (PVs) for ultrasensitive MRD detection in DLBCL 🧵https://t.co/JMFdV0Rc2U

[Ingo Ringshausen @i_ringshausen]

I am very happy to announce the 3rd Cambridge International Lymphoma symposium Dan Hodson @SCICambridge and I @uclcancer are organising. Save the dates…September 17&18- registration will open in May. Great lineup of speakers and focus on the TME!
#lymsm @CR_UK @bloodcancer_uk

[Matt Timmins @MatthewATimmins]

Many thanks to the @UkCll forum for a great meeting with some inspiring talks!

[Ingo Ringshausen @i_ringshausen]

Very happy to see our lab
member Matt Timmins @SCICambridge was awarded the 2024 Catovsky price from the @UkCll forum for his PhD project on stroma remodelling in B cell malignancies/ CLL. Congrats also to the co-winner Iona Ashworth from Sussex Medical School. Well done….!

[Ingo Ringshausen @i_ringshausen]

We are recruiting: If you are interested in tumour - microenvironment interactions & translational medicine (and looking for a new position), please apply for this ⁦@bloodcancer_uk⁩ funded project! https://t.co/sgA0rAcHQz

[Cambridge Stem Cell Institute @SCICambridge]

Registration is open for @Cambridge_Haem Cambridge Lymphoma Biology International Symposium this September! Check out their great line-up below, or register now https://t.co/asS1nqbKhs for the talks @Cambridge_Uni

[Ingo Ringshausen @i_ringshausen]

I am happy to share our latest data on the role of NOTCH1 in B cell malignancies #lymphoma #lymsm #CLL; immune-checkpoint blockade for the treatment of poor prognosis NOTCH1-mutated B cell malignancies?! https://t.co/BXShC22ny2

[Rebecca Caeser @CaeserRebecca]

🚨Latest paper from the Hodson Group @SCICambridge on how to expand and genetically modify primary human @GC B cells, providing a tool for high-throughput functional genetic screening and the creation of customized @lymphoma models! @NatureProtocols🧬🧑‍🔬✂️https://t.co/rxJ8gvdN31

[Ingo Ringshausen @i_ringshausen]

I am happy to share our latest paper: Thanks to all collaborators, a constructive review process @BloodJournal and congrats to Jingyu! https://t.co/BCH7oCSnL5. A step closer to understand ZAP-70 biology in #CLL , but still to tease out what exactly it does with ribosomes!

[Matt Timmins @MatthewATimmins]

Really interesting paper. AKT orchestrates development of RT via induction of Notch1 signaling in B cells, fueled by Dll1-expressing T cells. Supports work of ongoing PI3k trials. ?pAKT as biomarker of RT Risk?

[Blood Journals Portfolio @BloodPortfolio]

Active Akt signaling triggers #CLL toward Richter transformation via overactivation of Notch1 https://t.co/yzt2Elk3qt

[Matt Timmins @MatthewATimmins]

Significant paper for T-cell lymphoma field - FYN–TRAF3IP2 as a recurrent oncogenic gene fusion in AITL and PTCL-NOS

[Teresa Palomero @teresa_palomero]

Finally here, the latest work of the Ferrando and Palomero labs in @NatureCancer a wonderful way to start 2021 at https://t.co/UPS91WnkTC

[Michael Green, PhD @GreenLymphoLab]

Our latest paper is out in @NatureMedicine: Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. https://t.co/arN62qw2tk
Great @MDAndersonNews collaboration with @IamLinghua and Sattva Neelapu.

[CRCTU Haematology Team @CRCTU_Haem_Team]

AVAIL-T was the first trial to use a checkpoint inhibitor in PTCL. Serial blood samples are being used to estimate RHOA mutational burden, and for the high dimensional analysis of cell phenotype by #CyTOF. Publication is planned for 2021 (thread)

@DrChrisPFox @graham74GC @CRCTU

[Matt Timmins @MatthewATimmins]

Great work highlighting role of clonally diverse CD4+ T cells and innate effectors in the efficacy of PD-1 blockade in cHL https://t.co/RmeLetsurf

[Toby Eyre @tobyeyre82]

.@mattwilson2287 et al in @BloodAdvances
Large analysis of timing of HDMTX proph
334 RCHOP treated #DLBCL
i-MTX n=204 or EOT MTX n=130
⬆️ mucositis, NF, inpt days a/w i-HDMTX
No diff: OS, PFS, CNS relapse btwn grps
Recommend HDMTX pre d10 RCHOP if i-HDMTX
Great 🇬🇧 effort! #lymsm

[E. John Wherry @EJohnWherry]

Our paper on a detailed look an immunotypes in acute COVID-19 patients is out. Amazing team effort - so proud of all the authors involved here. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications https://t.co/3ZpuTcPbaN

[Matt Timmins @MatthewATimmins]

Impressive number of FL patients assessed by CyTOF. TIGIT+ T cells predict poor outcome in FL & specific TIGIT+ T cell subsets predict response to PD-1 therapy. An interesting receptor/target. https://t.co/vs1VKxAPpV

[Matt Timmins @MatthewATimmins]

Great thread - outlining unexpected lab results. Interesting animal to study. Why are naked mole rats so resistant to cancer - ?Tumour microenvironment/immune system related?

[Walid Khaled @WTKLAB]

I am glad to finally share this huge effort by @nude_mole_rat and the culmination of a great collaboration with @psalmotoxin that started nearly 6 years ago as a cool idea for a side project .....
https://t.co/KaevGeYAi5

[Michael Makris @ProfMakris]

Large retrospective US study of #COVID19 patients suggests that full anticoagulation does not offer a survival advantage. The question of the value of higher antithrombotic doses will remain as long as there are no good RCT results. https://t.co/BXzKRJWtdi

[Matt Timmins @MatthewATimmins]

Swaminathan et al - Interesting role of MYC suppressing NK maturation in the lymphoma microenvironment - Potential important implications for NK cell based therapies in MYC driven lymphomas. https://t.co/WMXoRmrnyz